S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

OncLive® On Air - Un podcast de OncLive® On Air

Essayez Nextory gratuitement pendant un mois.

Essayez Nextory gratuitement pendant un mois.

Un univers rempli de livres audio, cliquez ici pour essayer

 Sponsored
Podcast artwork

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Visit the podcast's native language site